Dr. Jörg Vollmer
Jörg Vollmer brings to Abalos Therapeutics significant knowledge and experience in the areas of immunology, oncology and infectious diseases, which he obtained in various R&D and executive positions over the course of his career. Most recently, Jörg was CSO at Rigontec GmbH where he helped advance a novel immuno-oncology treatment approach, a proprietary RIG-I RNA agonist into the clinic. He also led the company’s R&D efforts and pipeline expansion outside of oncology, until the acquisition by MSD in 2017.
Before joining Rigontec, he was CEO and Managing Director at Nexigen GmbH developing cell penetrating peptide therapeutics targeting tumor stem cell signaling pathways. Prior to this, he held the position of Managing Director and Site Head at Pfizer’s Oligonucleotide Therapeutics Unit in Düsseldorf, Germany where he was responsible for therapeutic oligonucleotide research and development.
Jörg started his career at Coley Pharmaceutical Group where he focused on the development of immune modulatory oligonucleotides targeting Toll-like receptors and held several positions leading up to Vice President Discovery Development before the company was acquired by Pfizer in 2008. Upon the acquisition he refocused Coley Pharmaceutical’s Düsseldorf site towards gene knock-down and transcriptional gene silencing technologies including RNA interference and antisense technologies.
Jörg studied biology at the Albert-Ludwigs-University in Freiburg and received a PhD from the Max-Planck-Institute of Immunobiology at the Department for Cellular Immunology in Freiburg, Germany. Jörg is also a member of the Scientific Advisory Boards of Silence Therapeutics and ProteoDesign.